Clinical Trial News and Research

RSS

$TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease$

TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease

TxCell SA, a biotechnology company developing novel and innovative, cost-effective personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it has enrolled the first patient in its phase IIb clinical trial of its lead product Ovasave in refractory Crohn’s disease.

4 Dec 2014

Study explores association between statin use and cataracts

Few classes of drugs have had such a transformative effect on the prevention of cardiovascular disease (CVD) as have statins, prescribed to reduce total cholesterol and low-density lipoprotein cholesterol.

4 Dec 2014

BTG agrees to acquire PneumRx for $475 million

PneumRx, Inc., a leader in the field of interventional pulmonology, today announced that it has signed an agreement to be acquired by BTG Plc in a deal worth up to $475 million, based on an initial consideration of $230 million and up to $245 million in performance-related milestone payments.

4 Dec 2014

Advanced prebiotic Bimuno has ability to reduce anxiety

Clasado Biosciences Limited, the producers and suppliers of the second generation prebiotic Bimuno (B-GOS), a unique trans-galactooligosaccharide, and the Department of Psychiatry, University of Oxford, today announce the results of clinical research demonstrating for the first time that an advanced prebiotic (Bimuno) has the ability to reduce anxiety.

4 Dec 2014

CytRx's clinical trials for aldoxorubicin placed on partial clinical hold

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the Company has received written notice from the United States Food and Drug Administration that its clinical trials for aldoxorubicin have been placed on partial clinical hold.

3 Dec 2014

Vital Therapies to use Veeva Vault applications to share clinical information

With an investigational combination biological product in Phase III clinical trials and a recent IPO, Vital Therapies, Inc. is readying its clinical and regulatory operations for global collaboration and greater efficiency with cloud-based Veeva Vault eTMF and Veeva Vault Submissions content management applications from Veeva Systems.

3 Dec 2014

Researchers find way to prevent noise-induced hearing loss

Researchers from Weill Cornell Medical College and the Gladstone Institutes have found a way to prevent noise-induced hearing loss in a mouse using a simple chemical compound that is a precursor to vitamin B3. This discovery has important implications not only for preventing hearing loss, but also potentially for treating some aging-related conditions that are linked to the same protein.

3 Dec 2014

AcelRx Pharmaceuticals' Zalviso device gets CE Mark approval

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device.

2 Dec 2014

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Apellis Pharmaceuticals, Inc., a leading biotechnology company applying immunotherapy to autoimmune disease, today announced that it has completed a $33M private placement of its Series C Preferred Stock.

2 Dec 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis will highlight more than 250 abstracts demonstrating advances in blood and breast cancer research at the upcoming American Society of Hematology (ASH) annual meeting December 6-9, and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 9-13.

2 Dec 2014

Ligand indazole chloride improves motor function, study shows

Multiple sclerosis (MS), an autoimmune disease of the brain and spinal cord, affects about 2.3 million people worldwide (400,000 in the United States). Affecting more women than men, it can be seen at any age, although it is most commonly diagnosed between the ages of 20 and 40.

2 Dec 2014

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

Alport Syndrome was first described by a physician called Cecil Alport, back in the late 1920s. It's a genetic disease that affects a certain type of collagen involved in the functioning of the kidney, the ear, and the eye.

1 Dec 2014

Endomagnetics gets FDA's IDE approval to begin clinical trial of SentiMag and Sienna+ system

Cancer healthcare company Endomagnetics announced today that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration to initiate a pivotal clinical trial to evaluate the safety and effectiveness of the SentiMag and Sienna+ magnetic sentinel lymph node biopsy system in the management of breast cancer.

1 Dec 2014

New vaccine shows promise in patients with metastatic breast cancer

A breast cancer vaccine developed at Washington University School of Medicine in St. Louis is safe in patients with metastatic breast cancer, results of an early clinical trial indicate. Preliminary evidence also suggests that the vaccine primed the patients' immune systems to attack tumor cells and helped slow the cancer's progression.

1 Dec 2014

iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics ("iCo" or "the Company"), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 Nov 2014

External artificial pancreas improves glucose control, reduces hypoglycemia risk

The world's first clinical trial comparing three alternative treatments for type 1 diabetes was conducted in Montréal by researchers at the IRCM and the University of Montreal, led by endocrinologist Dr. Rémi Rabasa-Lhoret.

27 Nov 2014

IQWiG comments on WHO Statement on Public Disclosure of Clinical Trial Results

The German Institute for Quality and Efficiency in Health Care (IQWiG) commented on the World Health Organization's (WHO) Statement on Public Disclosure of Clinical Trial Results.

27 Nov 2014

Researchers use EHRs to uncover hidden drug benefits

With research and development costs for many drugs reaching well into the billions, pharmaceutical companies want more than ever to determine whether their drugs already at market have any hidden therapeutic benefits that could warrant putting additional indications on the label and increase production.

27 Nov 2014

New research brings personalized cancer vaccine approach one step closer to reality

In the near future, physicians may treat some cancer patients with personalized vaccines that spur their immune systems to attack malignant tumors. New research led by scientists at Washington University School of Medicine in St. Louis has brought the approach one step closer to reality.

27 Nov 2014

Interventional X-ray guidance device may reduce radiation exposure of liver cancer patients

Johns Hopkins researchers report that their test of an interventional X-ray guidance device approved by the U.S. Food and Drug Administration in 2013 has the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy (IAT) for liver cancer.

27 Nov 2014

Clinical Trial News and Research

TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease

Study explores association between statin use and cataracts

BTG agrees to acquire PneumRx for $475 million

Advanced prebiotic Bimuno has ability to reduce anxiety

CytRx's clinical trials for aldoxorubicin placed on partial clinical hold

Vital Therapies to use Veeva Vault applications to share clinical information

Researchers find way to prevent noise-induced hearing loss

AcelRx Pharmaceuticals' Zalviso device gets CE Mark approval

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Ligand indazole chloride improves motor function, study shows

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

Endomagnetics gets FDA's IDE approval to begin clinical trial of SentiMag and Sienna+ system

New vaccine shows promise in patients with metastatic breast cancer

iCo Therapeutics announces corporate update and Q3 2014 financial results

External artificial pancreas improves glucose control, reduces hypoglycemia risk

IQWiG comments on WHO Statement on Public Disclosure of Clinical Trial Results

Researchers use EHRs to uncover hidden drug benefits

New research brings personalized cancer vaccine approach one step closer to reality

Interventional X-ray guidance device may reduce radiation exposure of liver cancer patients

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer